Published in

Future Medicine, Immunotherapy, 1(2), p. 37-56, 2010

DOI: 10.2217/imt.09.43

Links

Tools

Export citation

Search in Google Scholar

Directing dendritic cell immunotherapy towards successful cancer treatment

Journal article published in 2010 by Rachel Lubong Sabado, Nina Bhardwaj ORCID
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

The use of dendritic cells (DCs) for tumor immunotherapy represents a powerful approach for harnessing the patient’s own immune system to eliminate tumor cells. However, suboptimal conditions for generating potent immunostimulatory DCs, as well as the induction of tolerance and suppression mediated by the tumors and its microenvironment have contributed to limited success. Combining DC vaccines with new approaches that enhance immunogenicity and overcome the regulatory mechanisms underlying peripheral tolerance may be the key to achieving effective and durable anti-tumor immune responses that translate to better clinical outcomes.